<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:department>Division of Applied Medicine</gtr:department><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ECA42F9C-7939-4C8D-8F20-64C2875B157B"><gtr:id>ECA42F9C-7939-4C8D-8F20-64C2875B157B</gtr:id><gtr:firstName>Julie</gtr:firstName><gtr:otherNames>Clare</gtr:otherNames><gtr:surname>Crockett</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000435"><gtr:id>D101D220-95D5-49F4-B1C2-90B5D695FBC1</gtr:id><gtr:title>Defining the role of RANK in skeletal diseases associated with osteoclast dysfunction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000435</gtr:grantReference><gtr:abstractText>Receptor Activator of NFkB (RANK) is an important molecule within cells that break down bone called osteoclasts. Throughout life, osteoclasts work together with cells that form bone to keep bones healthy and strong. Many diseases occur when osteoclasts do not work properly which leads to either too much or not enough bone being broken down. This makes the bones weak and easily fractured. We are studying rare diseases that affect babies, children and young adults and are caused by changes in the gene for RANK. These diseases are osteopetrosis (that is caused by a lack of osteoclast formation) and early-onset Pagetic diseases (that are caused by overactive osteoclasts). In the laboratory, we are hoping to learn about which parts of the RANK molecule are most important for osteoclasts to form and work properly. Osteoporosis is a common disease where too much bone is broken down leading to bones that are less dense, weak and fracture easily, which causes a lot of pain and discomfort. In addition, the healthcare costs associated with the treatment of osteoporosis are #6 million per day. It is therefore important that we identify people at risk before their bones become weak and start to fracture. We will look at the RANK gene in a group of people who have had the density of their bones measured and identify whether there are any changes in the gene that can be linked to people with low bone density. This information will then be used to assemble a list of changes within RANK that, if present, can help to predict which people are likely to develop osteoporosis.</gtr:abstractText><gtr:technicalSummary>Receptor activator or NFkB (RANK) is critical for the formation, function and survival of bone-resorbing osteoclasts. A healthy skeleton is maintained by the balanced activities of osteoclasts and bone-forming osteoblasts. Mutations in RANK lead to the rare condition osteopetrosis and to early-onset Pagetic diseases. Polymorphisms in RANK are also associated with the common multi-factorial disease osteoporosis. In this project I will explore how mutations as found in the single-gene conditions caused by RANK affect receptor assembly, receptor turnover, ligand binding, and NFkB signalling in osteoclasts. In addition, I will screen a cohort of over 3000 women from the Aberdeen Prospective Osteoporosis Screening Study (APOSS) for known and novel polymorphisms in RANK. By analysing the functional consequences of such polymorphisms both individually and as haplotypes using the methodologies developed for the RANK mutations I will provide new knowledge on the role of RANK in maintaining bone mass and on its potential to act as an independent risk factor to help identify those at risk of osteoporosis.</gtr:technicalSummary><gtr:fund><gtr:end>2014-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>401576</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Aberdeen</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine &amp; Dentistry Aberdeen</gtr:department><gtr:description>Medical Genetics - sequencing</gtr:description><gtr:id>FA201AF1-D073-44C0-A4A3-E6F960E7CB98</gtr:id><gtr:impact>Sequencing data are now available for all regions of interest. Sequences will be analysed using appropriate software and specific single nucleotide polymorphisms genotyped. The Medical Genetics Department specialises in the identification of disease associated genetic variation. Their advice will be invaluable to select the most appropriate samples to carry forward for genotyping in our population of 3000 individuals.</gtr:impact><gtr:outcomeId>Wx4X887auEm-1</gtr:outcomeId><gtr:partnerContribution>Discussion and advice about PCR product sample preparation and Direct sequencing of targetted regions within our genomic DNA samples. Access and training on sequence analysis software.</gtr:partnerContribution><gtr:piContribution>Provided PCR-amplified samples for sequencing.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Structural and Molecular Biology</gtr:department><gtr:description>Protein purification and surface plasmon resonance analysis</gtr:description><gtr:id>3CC46145-485F-4723-8890-1D7E593BFADE</gtr:id><gtr:impact>Abstract submitted to American Society of Bone and Mineral Research, presented at the annual meeting in October 2013.</gtr:impact><gtr:outcomeId>Q6ZPrwUyxke-1</gtr:outcomeId><gtr:partnerContribution>Protein purification and surface plasmon resonance</gtr:partnerContribution><gtr:piContribution>Production of recombinant proteins using a mammalian expression system.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Aberdeen Open Doors</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>37BFF07A-7D4A-4D76-A975-F5DC0510EB3C</gtr:id><gtr:impact>Approximately 20 members of the public visited the Institute and I spoke about the type of research I am undertaking, with particular reference to the diseases that I am interested in. I showed the audience the types of cells that I study, how they are maintained and the type of information we can gather from them.

Positive feedback from audience.</gtr:impact><gtr:outcomeId>mjawxkGTvWt</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1 poster presentation at the ECTS conference in Prague, Czech Republic</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>388C539E-34C8-430A-B5E9-4FC1531561FF</gtr:id><gtr:impact>41st Meeting of the Eurpean Calcified Tissue Society; 17th-20th May 2014; Prague, Czech Republic; http://www.ectscongress.org/2014/
Study of the molecular effects of disease-causing mutations in RANK using human protein expression models
Subhajit Das, Janice Bramham, Angela Duthie, Susan Clark &amp;amp; Julie Crockett


A chance to discuss data with collaborators and other interested researchers.</gtr:impact><gtr:outcomeId>5382fe16242f31.82167262</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker, 7th International Workshop on Shwachmann Diamond Syndrome</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2C32B698-0FB8-4909-88BB-4FACB62967C9</gtr:id><gtr:impact>7th International Workshop on Shwachmann Diamond Syndrome, Toronto, Canada; 3rd-6th November 2013.
Invited speaker, presented talk describing &amp;quot;Genetic and in vitro studies into the pathophysiology of diseases of osteoclast dysfunction&amp;quot;.

Networking opportunity</gtr:impact><gtr:outcomeId>tMnNPLaH4Se</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.cepd.utoronto.ca/sds/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Science Week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4168A227-DAD7-49B4-92FC-06383AA0654A</gtr:id><gtr:impact>Members of the public attended our interactive stand at Satrosphere, Aberdeen over a 6 hour period and heard us discuss our research in the context of maintaining a healthy skeleton.

Science Week organiser received good feedback from attendees.</gtr:impact><gtr:outcomeId>pP8Bpx2WEvq</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>122661</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>0118F414-BE56-428D-8C96-1DF90FACFD48</gtr:id><gtr:outcomeId>qN2db8gar9n0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>laboratory training for FY1 medics within PGCERT</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>2E405728-A379-4B7C-94F5-1C4B67113413</gtr:id><gtr:outcomeId>Ap2dYszyGx5</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have requirements for the recapitulation of heterozygous phenotypes to assess the impact of disease-associated mutations on downstream signalling pathways. We have generated more than 15 different cell lines to explore the different mutations that are of interest to us, and the vectors used will be of use to any group wishing to do similar types of experiments.</gtr:description><gtr:id>FCA09BCF-62A8-4D62-8E8C-6F3C0648AC1B</gtr:id><gtr:impact>Allows investigation of the downstream effects of the mutations when the mutated proteins are expressed at levels that are representative of the physiological state. Will form the basis of the next significant research output.</gtr:impact><gtr:outcomeId>RejQnfVQZec</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Generation of bidirectional expression cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed in vitro assays to assess the effect of mutations associated with osteoclast-poor osteopetrosis on the localisation and signalling downstream from the RANK receptor.</gtr:description><gtr:id>5CF04AE3-4FDC-48F8-93C2-40729BC05298</gtr:id><gtr:impact>Critical to the acceptance of recent manuscript for publications in Journal of Bone and Mineral Research and Journal of Molecular Endocrinology.</gtr:impact><gtr:outcomeId>c3n98HBVzx1</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Truncating mutations in osteoclast-poor osteopetrosis</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Human recombinant RANK proteins (wildtype and 7 mutant proteins).</gtr:description><gtr:id>058CE32D-B554-49A6-8AF9-D2FD96C748F8</gtr:id><gtr:impact>Made possible the study of the effect of mutations in the extracellular domain of RANK on it's ability to interact with RANKL.</gtr:impact><gtr:outcomeId>hE2bzBLeMkR</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Generation of human recombinant RANK proteins in a mammalian expression system</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>61FB4811-6443-4C69-AEB8-6B54684348D6</gtr:id><gtr:title>Osteoporosis - a current view of pharmacological prevention and treatment.</gtr:title><gtr:parentPublicationTitle>Drug design, development and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a504a56bb9fa233e44d7ee8566f2030"><gtr:id>4a504a56bb9fa233e44d7ee8566f2030</gtr:id><gtr:otherNames>Das S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1177-8881</gtr:issn><gtr:outcomeId>pm_14024_24_23807838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E204C8E4-5BBD-4B31-993A-33D814DE98E4</gtr:id><gtr:title>RANK receptor oligomerisation in the regulation of NF?B signalling.</gtr:title><gtr:parentPublicationTitle>Journal of molecular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a504a56bb9fa233e44d7ee8566f2030"><gtr:id>4a504a56bb9fa233e44d7ee8566f2030</gtr:id><gtr:otherNames>Das S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0952-5041</gtr:issn><gtr:outcomeId>544ec3e3bec976.76698264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBD6958F-B101-4629-A74B-E602C7FD060C</gtr:id><gtr:title>RANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutations.</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acf5571efd7e7237173bf8cf668a47a8"><gtr:id>acf5571efd7e7237173bf8cf668a47a8</gtr:id><gtr:otherNames>Pangrazio A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn><gtr:outcomeId>pm_14024_24_22271396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB898407-5C5D-4BFD-97F0-715469FB2353</gtr:id><gtr:title>The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4606b56620eb6a095b1632c02dcb9523"><gtr:id>4606b56620eb6a095b1632c02dcb9523</gtr:id><gtr:otherNames>Mellis DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>pm_14024_24_21903860</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000435</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>